Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.

Solms, Alexander; Iorio, Alfonso; Ahsman, Maurice J; Vis, Peter; Shah, Anita; Berntorp, Erik; Garmann, Dirk

Solms, Alexander; Iorio, Alfonso; Ahsman, Maurice J; Vis, Peter; Shah, Anita; Berntorp, Erik; Garmann, Dirk.

Afiliación

Solms A; Research and Development, Pharmaceuticals, Clinical Pharmacometrics, Bayer AG, Müllerstraße 7, 13353, Berlin, Germany. alexander.solms@bayer.com.
Iorio A; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Ahsman MJ; Department of Medicine, McMaster University, Hamilton, ON, Canada.
Vis P; LAP&P Consultants BV, Leiden, The Netherlands.
Shah A; LAP&P Consultants BV, Leiden, The Netherlands.
Berntorp E; Bayer, Whippany, NJ, USA.
Garmann D; Centre for Thrombosis and Haemostasis, Lund University, Skåne University Hospital, Malmö, Sweden.

Clin Pharmacokinet ; 59(5): 605-616, 2020 05.

Article en En | MEDLINE | ID: mdl-31749076

Asunto(s)

Factor VIII/farmacocinética; Hemofilia A; Polietilenglicoles/farmacocinética; Adolescente; Adulto; Niño; Preescolar; Ensayos Clínicos como Asunto; Semivida; Hemofilia A/tratamiento farmacológico; Humanos; Masculino; Persona de Mediana Edad; Adulto Joven

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Polietilenglicoles / Factor VIII / Hemofilia A Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Child / Child, preschool / Humans / Male / Middle aged Idioma: En Revista: Clin Pharmacokinet Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google